Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-Alcoholic Steatohepatitis (NASH).

Sorrell1, Mukherjee

  • 1Gastroenterology and Hepatology Section, University of Nebraska Medical Center, Omaha, NE 68198-3285, USA msorrell@unmc.edu

Current Treatment Options in Gastroenterology
|November 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Two-stage cultivation of recombinant Saccharomyces cerevisiae to enhance plasmid stability under non-selective conditions: experimental study and modeling.

Enzyme and microbial technology·2000
Same author

4-Methyl-N-

Acta crystallographica. Section C, Crystal structure communications·2000
Same author

Intraoperative fentanyl reduces early vomiting after paediatric tonsillectomy compared with morphine

Paediatric anaesthesia·2000
Same author

An unusual seven-bond H-H spin coupling

Organic letters·2000
Same author

Fulminant Hepatic Failure.

Current treatment options in gastroenterology·2000
Same author

Effect of long-range forces on surface freezing

Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics·2000
Same journal

Esophageal Disorders in the Older Adult.

Current treatment options in gastroenterology·2025
Same journal

Endobariatrics: a Still Underutilized Weight Loss Tool.

Current treatment options in gastroenterology·2023
Same journal

Management of Post Ablative Barrett's Esophagus: a Review of Current Practices and Look at Emerging Technologies.

Current treatment options in gastroenterology·2023
Same journal

Inflammatory Bowel Disease Therapy and Venous Thromboembolism.

Current treatment options in gastroenterology·2023
Same journal

Ileal Pouch-Anal Anastomosis in the Older Adult: a Review of Postoperative Outcomes and Pouchitis Treatment.

Current treatment options in gastroenterology·2023
Same journal

Celiac Disease in the Elderly.

Current treatment options in gastroenterology·2023
See all related articles

Non-alcoholic steatohepatitis (NASH) is a common liver condition often diagnosed via biopsy. While lifestyle changes are key, ursodeoxycholic acid (UDCA) shows promise in managing liver tests, though new treatments are needed.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Internal Medicine

Background:

  • Non-alcoholic steatohepatitis (NASH) is a frequent cause of abnormal liver function tests.
  • Diagnosis requires excluding alcohol abuse and hepatitis C; liver biopsy is the gold standard.
  • Effective treatments for NASH remain limited.

Purpose of the Study:

  • To evaluate the role of ursodeoxycholic acid (UDCA) in managing NASH.
  • To assess the impact of UDCA on liver enzyme levels in NASH patients.
  • To highlight the importance of close patient monitoring in NASH management.

Main Methods:

  • Utilized ursodeoxycholic acid (UDCA) at a dosage of 15 mg/kg.
  • Monitored serial liver enzyme tests to assess treatment response.

Related Experiment Videos

  • Emphasized exclusion of other liver disease causes and biopsy for diagnosis.

    • Main Results:

    • UDCA administration often led to normalization of liver enzyme tests.
    • Despite normalized liver tests, histological progression of liver injury could still occur.
    • Close follow-up is essential as liver enzyme normalization does not guarantee disease resolution.

    Conclusions:

    • UDCA may help normalize liver tests in NASH patients.
    • Liver enzyme normalization does not preclude ongoing liver injury in NASH.
    • There is a critical need for novel, effective therapeutic agents for NASH, evaluated in controlled trials.